Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 30.9
(0.65%)
TWD 30.9
(0.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 286.05 Million TWD | 4.66% |
| 2022 | 273.32 Million TWD | 273.88% |
| 2021 | -157.19 Million TWD | -65.31% |
| 2020 | -95.09 Million TWD | -52.47% |
| 2019 | -62.36 Million TWD | 47.72% |
| 2018 | -119.29 Million TWD | -89.28% |
| 2017 | -63.02 Million TWD | 55.66% |
| 2016 | -142.15 Million TWD | -10.83% |
| 2015 | -128.26 Million TWD | -188.89% |
| 2014 | 144.29 Million TWD | -11.21% |
| 2013 | 162.51 Million TWD | 33.27% |
| 2012 | 121.94 Million TWD | 94.65% |
| 2011 | 62.64 Million TWD | -35.64% |
| 2010 | 97.33 Million TWD | -27.85% |
| 2009 | 134.91 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 78.86 Million TWD | 7.47% |
| 2024 Q1 | 73.37 Million TWD | -34.41% |
| 2023 FY | 286.05 Million TWD | 4.66% |
| 2023 Q1 | 101.84 Million TWD | 34777.74% |
| 2023 Q2 | 48.4 Million TWD | -52.47% |
| 2023 Q3 | 72.16 Million TWD | 49.09% |
| 2023 Q4 | 111.87 Million TWD | 55.03% |
| 2022 Q3 | 93.05 Million TWD | -15.4% |
| 2022 Q1 | 69.98 Million TWD | 247.8% |
| 2022 FY | 273.32 Million TWD | 273.88% |
| 2022 Q4 | 292 Thousand TWD | -99.69% |
| 2022 Q2 | 109.99 Million TWD | 57.17% |
| 2021 Q4 | 20.12 Million TWD | 112.58% |
| 2021 Q3 | -159.9 Million TWD | -3738.23% |
| 2021 FY | -157.19 Million TWD | -65.31% |
| 2021 Q1 | -13.25 Million TWD | 84.06% |
| 2021 Q2 | 4.39 Million TWD | 133.15% |
| 2020 Q4 | -83.18 Million TWD | -192.07% |
| 2020 Q1 | 13.11 Million TWD | 556.96% |
| 2020 Q2 | -25.46 Million TWD | -294.22% |
| 2020 FY | -95.09 Million TWD | -52.47% |
| 2020 Q3 | -28.48 Million TWD | -11.83% |
| 2019 Q4 | 1.99 Million TWD | 103.15% |
| 2019 Q3 | -63.38 Million TWD | 5.54% |
| 2019 FY | -62.36 Million TWD | 47.72% |
| 2019 Q1 | -17.26 Million TWD | 48.74% |
| 2019 Q2 | -67.09 Million TWD | -288.61% |
| 2018 FY | -119.29 Million TWD | -89.28% |
| 2018 Q2 | -37.24 Million TWD | -921.56% |
| 2018 Q1 | -3.64 Million TWD | -51.22% |
| 2018 Q4 | -33.68 Million TWD | 24.69% |
| 2018 Q3 | -44.72 Million TWD | -20.07% |
| 2017 Q1 | -30.19 Million TWD | -88.54% |
| 2017 Q4 | -2.41 Million TWD | 76.76% |
| 2017 Q3 | -10.37 Million TWD | 48.26% |
| 2017 FY | -63.02 Million TWD | 55.66% |
| 2017 Q2 | -20.04 Million TWD | 33.6% |
| 2016 Q3 | -39.32 Million TWD | 13.52% |
| 2016 FY | -142.15 Million TWD | -10.83% |
| 2016 Q4 | -16.01 Million TWD | 59.28% |
| 2016 Q2 | -45.47 Million TWD | -9.98% |
| 2016 Q1 | -41.34 Million TWD | -208.08% |
| 2015 FY | -128.26 Million TWD | -188.89% |
| 2015 Q1 | -66.3 Million TWD | -257.17% |
| 2015 Q2 | -29.02 Million TWD | 56.22% |
| 2015 Q4 | 38.25 Million TWD | 153.73% |
| 2015 Q3 | -71.19 Million TWD | -145.27% |
| 2014 Q4 | 42.18 Million TWD | 165.79% |
| 2014 Q2 | 102.67 Million TWD | 61.53% |
| 2014 Q1 | 63.56 Million TWD | 116.71% |
| 2014 FY | 144.29 Million TWD | -11.21% |
| 2014 Q3 | -64.12 Million TWD | -162.45% |
| 2013 Q1 | -14.12 Million TWD | -188.32% |
| 2013 Q3 | 98.44 Million TWD | 101.51% |
| 2013 Q4 | 29.33 Million TWD | -70.21% |
| 2013 FY | 162.51 Million TWD | 33.27% |
| 2013 Q2 | 48.85 Million TWD | 445.93% |
| 2012 Q4 | 15.99 Million TWD | -64.13% |
| 2012 Q3 | 44.58 Million TWD | 14.72% |
| 2012 FY | 121.94 Million TWD | 94.65% |
| 2012 Q2 | 38.86 Million TWD | 57.78% |
| 2012 Q1 | 24.63 Million TWD | 282.04% |
| 2011 Q2 | 22.37 Million TWD | -19.31% |
| 2011 Q1 | 27.73 Million TWD | -4.84% |
| 2011 Q3 | 6.08 Million TWD | -72.81% |
| 2011 Q4 | 6.44 Million TWD | 5.95% |
| 2011 FY | 62.64 Million TWD | -35.64% |
| 2010 Q3 | 5.43 Million TWD | -84.72% |
| 2010 FY | 97.33 Million TWD | -27.85% |
| 2010 Q1 | 27.15 Million TWD | 0.0% |
| 2010 Q4 | 29.14 Million TWD | 435.87% |
| 2010 Q2 | 35.6 Million TWD | 31.1% |
| 2009 FY | 134.91 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 141.71 Million TWD | -101.852% |
| Panion & Bf Biotech Inc. | 156.82 Million TWD | -82.4% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 280.8 Million TWD | -1.869% |
| GenMont Biotech Incorporation | 6.98 Million TWD | -3993.532% |
| Abnova (Taiwan) Corporation | 47.19 Million TWD | -506.128% |
| Adimmune Corporation | -722.74 Million TWD | 139.579% |
| Tanvex BioPharma, Inc. | -2.1 Billion TWD | 113.617% |
| Polaris Group | -1.84 Billion TWD | 115.487% |
| Energenesis Biomedical CO.,LTD. | -261.83 Million TWD | 209.25% |
| UnicoCell Biomed Co., Ltd. | -96.28 Million TWD | 397.108% |
| PELL Bio-Med Technology Co. Ltd. | -411.24 Million TWD | 169.558% |